Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma
- 1 February 2007
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 175 (3), 235-242
- https://doi.org/10.1164/rccm.200603-416oc
Abstract
Asthma treatment guidelines recommend addition of controller medications for patients with poorly controlled asthma. We compared the effectiveness of once-daily oral controller therapy with either an antileukotriene receptor antagonist (montelukast) or low-dose theophylline added to existing medications in patients with poorly controlled asthma. We conducted a randomized, double-masked, placebo-controlled trial in 489 participants with poorly controlled asthma randomly assigned to placebo, theophylline (300 mg/d), or montelukast (10 mg/d). Participants were monitored for 24 wk to measure the rate of episodes of poor asthma control (EPACs) defined by decreased peak flow, increased beta-agonist use, increased oral corticosteroid use, or unscheduled health care visits. There was no significant difference in EPAC rates (events/person/yr) compared with placebo: low-dose theophylline, 4.9 (95% confidence interval [CI], 3.6-6.7; not significant); montelukast, 4.0 (95% CI, 3.0-5.4; not significant); and placebo, 4.9 (95% CI, 3.8-6.4). Both montelukast and theophylline caused small improvements in prebronchodilator FEV(1) of borderline significance. Nausea was more common with theophylline only during the first 4 wk of treatment. Neither treatment improved asthma symptoms or quality of life. However, in patients not receiving inhaled corticosteroids, addition of low-dose theophylline significantly (p < 0.002) improved asthma control and symptoms as well as lung function. Neither montelukast nor low-dose theophylline lowered the EPAC rate of poor asthma control in patients with poorly controlled asthma despite improved lung function. For patients not using inhaled corticosteroids, low-dose theophylline improved asthma symptom control more than montelukast or placebo, and provides a safe and low-cost alternative asthma treatment.Keywords
This publication has 40 references indexed in Scilit:
- Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthmaPublished by Wiley ,2004
- Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidenceBMJ, 2003
- Theophylline Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear CellsInternational Archives of Allergy and Immunology, 2002
- Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophagesThe FASEB Journal, 2001
- Non-invasive ventilation for acute exacerbations of COPD: a new standard of careThorax, 2000
- Development and validation of a questionnaire to measure asthma controlEuropean Respiratory Journal, 1999
- Anti-inflammatory Effects of Theophylline: Modulation of Cytokine ProductionAnnals of Allergy, Asthma & Immunology, 1996
- Determination of MK-0476 in human plasma by liquid chromatographyJournal of Pharmaceutical and Biomedical Analysis, 1995
- Anti-inflammatory effects of low-dose oral theophylline in atopic asthmaThe Lancet, 1994
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986